argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China Read more about argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
Zai Lab Announces Upcoming Presentation at 39th Annual J.P. Morgan Healthcare Conference Read more about Zai Lab Announces Upcoming Presentation at 39th Annual J.P. Morgan Healthcare Conference
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List Read more about Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List
Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China Read more about Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China
Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer Read more about Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
Zai Lab Appoints Alan Sandler, M.D., as President, Head of Global Development, Oncology Read more about Zai Lab Appoints Alan Sandler, M.D., as President, Head of Global Development, Oncology
Zai Lab Partner Five Prime Therapeutics Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric or Gastroesophageal Junction Canc Read more about Zai Lab Partner Five Prime Therapeutics Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric or Gastroesophageal Junction Canc
Zai Lab Announces First Patient Dosed in China in a Potentially Registrational Study of Retifanlimab in Patients with Endometrial Cancer Read more about Zai Lab Announces First Patient Dosed in China in a Potentially Registrational Study of Retifanlimab in Patients with Endometrial Cancer
Zai Lab Announces Upcoming Presentations in November Investor Conferences Read more about Zai Lab Announces Upcoming Presentations in November Investor Conferences
Zai Lab Announces Full Exercise of the Over-allotment Option Read more about Zai Lab Announces Full Exercise of the Over-allotment Option